Meals, blood and fat
The same word—peptide—covers experiments whose subjects, measurements and conclusions have little in common.
Four subjects on the screen
A meal gives the ipamorelin story a useful centre. Yet comparing every compound by its success at “recovery” would blur the rest of the collection. Tesamorelin investigators scanned fat in adults with HIV; CJC-1295 investigators tracked hormones in healthy volunteers; MOTS-c experiments entered cells and animal muscle.
I’d start a comparison by choosing the thing that changed. This is the resulting programme:
| Compound | Setting and measurement | Result |
|---|---|---|
| Ipamorelin | People after bowel resection; first tolerated meal | The primary endpoint was missed. Faster return to eating was not established. |
| CJC-1295 with DAC | Healthy adults; growth hormone and IGF-1 | Sustained hormone increases, with pulses persisting in a separate study of healthy men. |
| Tesamorelin | Adults with HIV and abnormal abdominal fat accumulation; internal fat measurements | Reduced visceral and liver fat. |
| MOTS-c | Cultured cells and mice; metabolic signalling and muscle | Changes in energy handling and tissue-specific CK2 activity. |
Each result can stand on its own. None of these studies compared all four compounds head to head.
The blood result that stayed quiet
Ipamorelin increased longitudinal bone growth in adult female rats without changing total circulating IGF-1. CJC-1295’s best-known human result runs through increased IGF-1. Putting the two side by side makes the blood test feel less like a universal verdict.
I wouldn’t infer human bone growth from those rats, or a failure of all hormone testing from one experiment. The useful question is narrower: which measurement captures the action in this tissue and this setting? The ipamorelin article follows that puzzle further.
Fat during continued treatment
Tesamorelin has direct clinical evidence for reduced internal fat in its studied HIV population. The longer programme also documented fat reaccumulation after treatment stopped. That changes how a reader can understand the successful on-treatment result.
CJC-1295’s prolonged blood response leaves broader outcomes unestablished, while MOTS-c’s human dialysis cohort measured a risk association with the body’s own peptide. I expect clearer answers once each of those very different findings retains its proper subject. A question about growth hormone research can then be answered with the experiment that actually addressed it.